Monopar Therapeutics (MNPR) EBT (2017 - 2026)
Monopar Therapeutics (MNPR) posted EBT of -$4.3 million for Q3 2025, down 65.64% sequentially from -$2.6 million in Q2 2025, and down 189.36% YoY from $4.8 million in Q3 2024.
Monopar Therapeutics (MNPR) EBT (2017 - 2026) Analysis & Trends
Monopar Therapeutics has reported EBT for 9 years, with the latest figure at -$4.3 million in Q3 2025.
- Quarterly EBT fell 189.36% year-over-year to -$4.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$11.5 million (down 66.83% YoY) and the FY2025 annual result came in at -$13.7 million, up 11.45% from the prior year.
- EBT declined to -$4.3 million in Q3 2025 per MNPR's latest filing, from -$2.6 million in the prior quarter.
- Over five years, EBT peaked at -$1.5 million in Q3 2024 and troughed at -$13.4 million in Q4 2022.
- A 5-year average of -$3.5 million and a median of -$2.5 million in 2021 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2025: EBT jumped 31.6% in 2024, then tumbled 189.36% in 2025.
- Over 5 years, EBT stood at -$10.4 million in 2021, then slipped by 29.03% to -$13.4 million in 2022, then soared by 85.44% to -$2.0 million in 2023, then grew by 24.47% to -$1.5 million in 2024, then sank by 189.36% to -$4.3 million in 2025.
- According to Business Quant data, EBT over the past three periods registered -$4.3 million, -$2.6 million, and -$3.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | -5.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.57 Mn |
| Sep 30, 2025 | -4.27 Mn |
| Jun 30, 2025 | -2.58 Mn |
| Mar 31, 2025 | -3.22 Mn |
| Sep 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | -1.79 Mn |
| Mar 31, 2024 | -1.70 Mn |
| Sep 30, 2023 | -1.95 Mn |
| Jun 30, 2023 | -2.35 Mn |
| Mar 31, 2023 | -2.49 Mn |
| Dec 31, 2022 | -13.42 Mn |
| Sep 30, 2022 | -2.41 Mn |
| Jun 30, 2022 | -2.85 Mn |
| Mar 31, 2022 | -2.46 Mn |
| Dec 31, 2021 | -10.40 Mn |
| Sep 30, 2021 | -2.46 Mn |
| Jun 30, 2021 | -2.09 Mn |
| Mar 31, 2021 | -1.89 Mn |
| Dec 31, 2020 | -7.48 Mn |
| Sep 30, 2020 | -1.65 Mn |